The store will not work correctly when cookies are disabled.
3-(6-Amino-pyridin-3-yl)-N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)-acrylamide
ID: ALA297053
Chembl Id: CHEMBL297053
PubChem CID: 5287720
Max Phase: Preclinical
Molecular Formula: C19H20N4O
Molecular Weight: 320.40
Molecule Type: Small molecule
Associated Items:
Names and Identifiers
Canonical SMILES: CN(Cc1cc2ccccc2n1C)C(=O)/C=C/c1ccc(N)nc1
Standard InChI: InChI=1S/C19H20N4O/c1-22(19(24)10-8-14-7-9-18(20)21-12-14)13-16-11-15-5-3-4-6-17(15)23(16)2/h3-12H,13H2,1-2H3,(H2,20,21)/b10-8+
Standard InChI Key: AKFPMLBVLWZSQX-CSKARUKUSA-N
Associated Targets(Human)
Associated Targets(non-human)
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Calculated Properties
| Molecular Weight: 320.40 | Molecular Weight (Monoisotopic): 320.1637 | AlogP: 2.83 | #Rotatable Bonds: 4 |
| Polar Surface Area: 64.15 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 6.45 | CX LogP: 2.29 | CX LogD: 2.25 |
| Aromatic Rings: 3 | Heavy Atoms: 24 | QED Weighted: 0.75 | Np Likeness Score: -0.52 |
References
| 1. Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF.. (2003) Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK., 46 (9): [PMID:12699381] [10.1021/jm0204035] |
| 2. Miller WH, Seefeld MA, Newlander KA, Uzinskas IN, Burgess WJ, Heerding DA, Yuan CC, Head MS, Payne DJ, Rittenhouse SF, Moore TD, Pearson SC, Berry V, DeWolf WE, Keller PM, Polizzi BJ, Qiu X, Janson CA, Huffman WF.. (2002) Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)., 45 (15): [PMID:12109908] [10.1021/jm020050+] |
| 3. Tipparaju SK, Muench SP, Mui EJ, Ruzheinikov SN, Lu JZ, Hutson SL, Kirisits MJ, Prigge ST, Roberts CW, Henriquez FL, Kozikowski AP, Rice DW, McLeod RL.. (2010) Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase., 53 (17): [PMID:20698542] [10.1021/jm9017724] |
| 4. Rana P, Ghouse SM, Akunuri R, Madhavi YV, Chopra S, Nanduri S.. (2020) FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors., 208 [PMID:32883635] [10.1016/j.ejmech.2020.112757] |
